24-Hour IOP-Lowering Effect of Brimonidine 0.1%
Information source: Allergan
Information obtained from ClinicalTrials.gov on November 03, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Open-Angle Glaucoma; Ocular Hypertension
Intervention: brimonidine 0.1% (Alphagan® P) (Drug)
Phase: Phase 4
Status: Recruiting
Sponsored by: Allergan Official(s) and/or principal investigator(s):
Medical Affairs, Study Director, Affiliation: Allergan
Overall contact:
Allergan Inc., Email: clinicaltrials@allergan.com
Summary
This study will evaluate the efficacy and safety of brimonidine 0. 1% three-times daily in
patients with glaucoma or ocular hypertension
Clinical Details
Study design: Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Safety/Efficacy Study
Primary outcome: mean IOP for 24-hour period at 4 weeks
Secondary outcome: ocular perfusion pressure
Eligibility
Minimum age: 40 Years.
Maximum age: 80 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- patients with open-angle glaucoma or ocular hypertension
Exclusion Criteria:
- allergy to brimonidine
- inability to complete 24 hour stay for monitoring
Locations and Contacts
Allergan Inc., Email: clinicaltrials@allergan.com
San Diego, California, United States; Recruiting
Additional Information
Starting date: December 2006
Ending date: February 2008
Last updated: May 5, 2008
|
